Gapping up
In reaction to earnings/guidance:
- JEF +3.2%
Other news:
- CERE +45.3% (reports topline results for CVL-231 in Phase 1b clinical trial)
- VBIV +6.5% (announces initial positive phase 1 data for its evlp vaccine candidate against COVID-19)
- ORTX +5.6% (provides regulatory and clinical updates for lead gene therapy programs)
- HITI +5.3% (announces that its Canna Cabana stores have begun selling recreational cannabis products for adult use)
- CSIQ +4.1% (awarded 86 MWp in Japan's 8th solar energy auction)
- SND +3.9% (reaches settlement with U.S. Well Services)
- PLBY +3.5% (to acquire Honey Birdette for $333 mln)
- MS +3.2% (doubles dividend following Fed stress test)
- FTCI +2.3% (sells its stake in Dimension Energy for $22 mln)
- KUKE +2.3% (announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to $1 mln of its ADRs through December 31)
- CHMA +1.9% (submits MAA to the EMA seeking approval of MYCAPSSA)
- ZEAL +1.6% (to initiate a share repurchase program)
- RIGL +1.6% (Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial)
- USB +1.5% (to recommend increase of dividend following Fed stress test)
- GS +1.3% (to increase dividend following Fed stress test)
Analyst comments:
- RARE +8.8% (upgraded to Buy from Neutral at BofA Securities; tgt $162)
- TXT +3.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CSX +2.6% (upgraded to Buy from Neutral at Citigroup)